|
|
Article: Indications for Merck's SINGULAIR(R) Expand with FDA Approval for Perennial Allergic Rhinitis; SINGULAIR Now Shown to Provide Relief from a Broad Range of Indoor and Outdoor Allergy Symptoms.
- Article from:
- Business Wire
- Article date:
- August 18, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SINGULAIR(R) (montelukast sodium) for the relief of symptoms of perennial allergic rhinitis (PAR), or indoor allergies, in adults and children six months of age and older. A convenient once-a-day tablet, SINGULAIR has been proven to help relieve a broad range of indoor and outdoor allergy symptoms for up to 24 hours.
"Allergic rhinitis is one of the most common allergic conditions today, with approximately 50 million people in the United States suffering some form of the condition," said Gailen Marshall Jr., M.D., Ph.D., director of the ...